Is Targeting Neoantigens the Next Frontier in Cancer Immunotherapy?
At the recent scientific meeting to celebrate the 40th anniversary of the Centre d’Immunologie de Marseille-Luminy (#CIML40), Professor Ton Schumacher from the Netherlands Cancer Institute gave an informative presentation on “T cell recognition and tumor resistance in human cancer.”
Picture Credit: ATGC Partners
Schumacher started his talk at CIML by saying, “I guess by now I should consider myself a cancer immunologist…”
Cancer immunologist ‘wannabes’ should take note of the level of expertise required to be considered one!
He is one of the co-founders of Neon Therapeutics and a leading researcher into antigen-specific T cell immunity.
Several companies are seeking to develop personalized cancer vaccines against patient-specific neoantigens.
We previously wrote about the approach Neon Therapeutics is following based on expert interviews with the interim CEO Cary Pfeffer and scientific co-founder Dr Cathy Wu.
Yesterday the field heated up when it was announced that German biotech BioNTech AG had entered a strategic collaboration with Genentech to develop individualized mRNA cancer therapies (Sept 20, 2016 press release).
This post continues the BSB mini-series on targeting neoantigens that we started last month. Do check out previous posts if you missed them:
- What are neoantigens and why do they matter in cancer immunotherapy?
- Neon shines the light on Neoantigen targeted Cancer Immunotherapy
- Can neoantigen vaccines make a difference in cancer research?
After his #CIML40 presentation, Prof Schumacher kindly spoke to BSB.
Subscribers can login to read more or you can purchase access.
This content is restricted to subscribers
